Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice
British Journal of Pharmacology2023Vol. 181(7), pp. 1091–1106
Citations Over TimeTop 10% of 2023 papers
Taiji Miyake, Tatsuki Mochizuki, Toshito Nakagawa, Mikiko Nakamura, Chie Emoto, Natsuko Komiyama, Manabu Hirabayashi, Satoshi Tsuruta, Tomofumi Shimojo, Kimio Terao, Tatsuhiko Tachibana
Abstract
CYP3A-mediated DDI can be predicted by correctly estimating human fm,CYP3A,in vivo using Hu-PXB mice. These mice could be useful predicting hepatic fm and ft,efflux .
Related Papers
- → The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study(2009)22 cited
- → Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity(2012)37 cited
- → Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam(2006)29 cited
- Effects of ketoconazole on rat liver cytochrome P450(2007)
- → Actin Organization as an in Vitro Assay for Tumorigenicity(1982)2 cited